U.S. markets closed
  • S&P Futures

    3,842.00
    +32.75 (+0.86%)
     
  • Dow Futures

    31,140.00
    +228.00 (+0.74%)
     
  • Nasdaq Futures

    13,059.75
    +148.75 (+1.15%)
     
  • Russell 2000 Futures

    2,235.00
    +35.80 (+1.63%)
     
  • Crude Oil

    62.51
    +1.01 (+1.64%)
     
  • Gold

    1,748.80
    +20.00 (+1.16%)
     
  • Silver

    26.96
    +0.52 (+1.97%)
     
  • EUR/USD

    1.2085
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3981
    +0.0059 (+0.42%)
     
  • USD/JPY

    106.5310
    +0.0290 (+0.03%)
     
  • BTC-USD

    46,521.37
    +1,033.65 (+2.27%)
     
  • CMC Crypto 200

    929.49
    -3.65 (-0.39%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,568.11
    +602.10 (+2.08%)
     

Zymeworks to Participate in Upcoming Investor Conferences and Events

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced today that management will participate in five upcoming virtual investor conferences.

  • Guggenheim Healthcare Talks Oncology Days, February 11-12, 2021. Zymeworks will be participating in the event; there is no public presentation.

  • SVB Leerink’s 10th Annual Global Healthcare Conference, February 22-26, 2021. Zymeworks will be participating in the conference, there is no public presentation.

  • Raymond James’ 42nd Annual Institutional Investor Conference, March 1-3, 2021. Zymeworks will be participating in the conference; there is no public presentation.

  • Barclays’ Global Healthcare Conference, March 9-11, 2021. Zymeworks is presenting on Thursday, March 11, 2021 at 1:15 p.m. ET.

  • Citi's 2021 Winter West Coast Biotech Virtual Bus Tour, March 16-17, 2021. Zymeworks will be participating in the event; there is no public presentation.

Interested parties can access a live webcast of the Barclays presentation via a link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations, which will also host a recorded replay available afterwards.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab (ZW25), is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently enrolling in a pivotal clinical trial for refractory HER2-amplified biliary tract cancer (HERIZON-BTC-01) as well as several Phase 2 clinical trials for HER2-expressing gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2-targeting antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005760/en/

Contacts

Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com

Tiffany Tolmie
(604) 678-1388
ir@zymeworks.com

Media Inquiries:
Mary Klem
(604) 678-1388
media@zymeworks.com